Cargando…
克里唑替尼治疗晚期非小细胞肺癌的临床研究进展
At present, in the treatment of non-small cell lung cancer (NSCLC), targeted therapy has an important status. After epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs), crizotinib targeted at EML4-ALK fusion gene becomes a significant drug of molecular targeted therapy in NSCLC. P...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000565/ https://www.ncbi.nlm.nih.gov/pubmed/23769348 http://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.09 |